Vir Biotechnology (VIR) Common Equity (2018 - 2026)

Vir Biotechnology's Common Equity history runs 9 years deep, the most recent figure standing at $812.8 million for Q1 2026.

• In Q1 2026, Common Equity fell 22.14% year-over-year to $812.8 million; the TTM figure through Mar 2026 stood at $812.8 million (down 22.14% YoY), while the FY2025 annual figure was $765.3 million, down 33.48% from the prior year.
• Common Equity came in at $812.8 million for Q1 2026 at Vir Biotechnology, up from $765.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $2.1 billion in Q3 2022 to a low of $765.3 million in Q4 2025.
• A 5-year average of $1.5 billion and a median of $1.5 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 207.4% in 2022 and slumped 35.84% in 2025, its largest moves.
• Vir Biotechnology's Common Equity stood at $2.1 billion in 2022, then slipped by 23.47% to $1.6 billion in 2023, then decreased by 27.66% to $1.2 billion in 2024, then tumbled by 33.48% to $765.3 million in 2025, then advanced by 6.21% to $812.8 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $812.8 million, $765.3 million, and $796.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison